1. Home
  2. BGC vs ACAD Comparison

BGC vs ACAD Comparison

Compare BGC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BGC Group Inc.

BGC

BGC Group Inc.

HOLD

Current Price

$9.46

Market Cap

4.4B

Sector

Finance

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$23.12

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGC
ACAD
Founded
1945
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
4.4B
IPO Year
1999
2004

Fundamental Metrics

Financial Performance
Metric
BGC
ACAD
Price
$9.46
$23.12
Analyst Decision
Strong Buy
Buy
Analyst Count
2
22
Target Price
$14.50
$29.95
AVG Volume (30 Days)
2.1M
1.3M
Earning Date
02-12-2026
02-25-2026
Dividend Yield
0.89%
N/A
EPS Growth
36.46
98.53
EPS
0.33
1.54
Revenue
$2,640,884,000.00
$1,047,118,000.00
Revenue This Year
$36.53
$15.16
Revenue Next Year
$11.33
$11.24
P/E Ratio
$27.14
$15.29
Revenue Growth
24.59
12.69
52 Week Low
$7.24
$13.40
52 Week High
$10.96
$28.35

Technical Indicators

Market Signals
Indicator
BGC
ACAD
Relative Strength Index (RSI) 61.25 32.29
Support Level $8.81 $23.37
Resistance Level $9.18 $26.23
Average True Range (ATR) 0.29 1.00
MACD 0.02 -0.37
Stochastic Oscillator 88.89 2.82

Price Performance

Historical Comparison
BGC
ACAD

About BGC BGC Group Inc.

BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: